Dr Magliocco CEO and President of Protean BioDiagnostics will be a panelist discussing the impact of digital pathology on precision medicine diagnostics at the Precision Medicine Leaders Summit East in Philadelphia June 11 and 12
Protean BioDiagnostics has recently partnered with the AI technology leader Nucleai to comercialize advanced AI based diagnostics into the US pathology market with an initial target focus on improving quality of prostate cancer pathology diagnosis in urology practices